Daklinza
NDC Package 0003-0213-01

The code 0003-0213-01 identifies a specific commercial package of 28 tablet in 1 bottle of Daklinza, labeled by E.r. Squibb & Sons, L.l.c.. This product is billed for "EA" each discreet unit and contains an estimated amount of 28 billable units per package. This is formulated for use and contains as the active substance.

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by E.r. Squibb & Sons, L.l.c. on July 27, 2015. The current certification is valid through June 30, 2020.

Daclatasvir is used with another antiviral medication (sofosbuvir) to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. Daclatasvir should never be used without sofosbuvir. Daclatasvir and sofosbuvir may also be used with another antiviral medication (ribavirin). These medications together reduce the amount of hepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer. It is not known if this treatment can prevent you from passing the virus to others. Do not share needles, and practice "safer sex" (including the use of latex condoms) to lower the risk of passing the virus to others.

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00003021301. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 28 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.